EUCTR2008-008554-23-SE进行中（未招募）不适用
eutralizing Antibodies to Interferon beta in patients treated with Rebif New Formulation - NAb development with RNF
The Multiple Sclerosis Research Group, Department of Clinical Neuroscience0 个研究点目标入组 100 人开始时间: 2009年6月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.IFNß naïve MS patients with RRMS.
- •2.18-60 years old.
- •3.Patients who have agreed to initiate treatment with RNF
- •4.Patients who have given signed consent to participate in the study.
- •5.Women shall not be pregnant and shall not have the intention of becoming pregnant during the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patients with a previous treatment history of IFNß or IFN?.
- •2.Patients with a positive NAb test before initiation of RNF.
- •3.Patients treated with glatiramer acetate, IVIG or natalizumab within the previous 3 months.
- •4.Patients treated with immunosuppressive treatments such as mitoxantrone, alemtuzumab or azathioprine during the previous 6 months.
- •5.Patients with relevant non-MS condition potentially complicating IFNß treatment.
- •6.Contraindication for interferon beta treatment as per SPC.
- •7.Women that becomes pregnant.
研究者
相似试验
招募中
不适用
eutralizing antibody of Interferon beta on multiple sclerosis (Multi-center clinical studies)Multiple sclerosisJPRN-UMIN000008186Yokohama City University100
进行中（未招募）
1 期
Antiviral and Immunomodulatory Interferon-Beta in high-risk COVID-19 patientsSARS-CoV 2 infection characterized by a National Early Warning Score lower or equal to 2 and symptoms present for less than 7 daysMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862MedDRA version: 20.0Level: PTClassification code 10070255Term: Coronavirus test positiveSystem Organ Class: 10022891 - InvestigationsEUCTR2020-003872-42-ITIstituto di Farmacologia Traslazionale - CNR60
已完成
不适用
Assay for detection of neutralizing antibodies against interferon-beta in multiple sclerosismultiple sclerosisJPRN-UMIN000005797Department of Neurology, Tohoku University School of Medicine100
进行中（未招募）
不适用
atalizumab de-escalation to interferon-beta-1b in patients withrelapsing-remitting multiple sclerosis: A multicenter studyEUCTR2012-004040-30-ATOspedale Regionale di Lugano72
进行中（未招募）
不适用
REsPons på interferon-Alfa hos InterfeRon-ß-neutraliserende antistof-positive patienter med multipel sklerose - REPAIRMedDRA version: 12.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisMultiple SclerosisEUCTR2009-016824-29-DKDansk Multipel Sclerose Center10